Firm record
ALK-Abelló A/S
▲Listed·Denmark·GICS Pharmaceuticals, Biotechnology and Life Sciences·LEI 529900SGCREUZCZ7P020
Partial profile
We haven't fully researched ALK-Abelló A/S yet.
Request a full evidence-chained profile — we'll dig into their carbon, nature, social & water disclosure, find their facilities and sources, and email you when it's ready.
We’ll only use your email to notify you about this request.
Targets & commitments3
| Source | Type | Scope | Base | Target year | Value | Status |
|---|---|---|---|---|---|---|
| sbti | — | — | — | — | — | — |
| sbti | near_term | 3 | 2022 | 2028 | 80% | — |
| sbti | near_term | Scope 1 + 2 | 2022 | 2030 | 42% | 1.5°C |
Identifiers
| lei | 529900SGCREUZCZ7P020 |
| isin | DK0061802139 |
| sbti_id | 40007659 |
| ticker | ALK-B.CO |
| Reverberate ID | 5933a01d… |